TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36724001
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent or combination therapy (inactive trials)
Study: 36724001
Drug: SARC006 trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARC006 trial (upfront chemotherapy in chemotherapy naïve patients)
Study: 36724109
Drug: Zuranolone, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuranolone, dosage and duration not available
Study: 36724193
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500mg twice daily for 8 weeks
Study: 36724311
Drug: Usual insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual insulin pump (UP)
Study: 36724311
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin delivery (AID) (MiniMed™ 780G)
Study: 36724328
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (hypothermia + machine perfusion)
Study: 36724328
Drug: Hypothermia vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia vs Combination Therapy
Study: 36724328
Drug: Combination Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Therapy vs Machine Perfusion
Study: 36724401
Drug: Smartwatch prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartwatch prescription for AF
Study: 36724434
Drug: Semisuperboosted LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semisuperboosted LPV/r (adding a ritonavir 100 mg crushed tablet)
Study: 36724434
Drug: Rifampicin co-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin co-treatment
Study: 36724515
Drug: Olutasidenib (FT-2102)
Normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olutasidenib (FT-2102) 150 mg twice daily
Study: 36724759
Drug: Convection-enhanced delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection-enhanced delivery of autologous cerebrospinal fluid (CSF) at a convective rate of 5 µL/min with a maximum volume of infusion of 500 mL
Study: 36725084
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A)
Study: 36725084
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A1)
Study: 36725090
Drug: CDED+antibiotics (azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDED+antibiotics (azithromycin 7.5 mg/kg and metronidazole 20 mg/kg)
Study: 36725090
Drug: CDED+antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDED+antibiotics
Study: 36725117
Drug: GPRC5D-targeted CAR
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPRC5D-targeted CAR T cells (OriCAR-017) administered as a single dose of intravenous 1 × 10^6 cells/kg
Study: 36726737
Drug: Benralizumab 10
Normalized name: BENRALIZUMAB 10MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 10 mg
Study: 36726737
Drug: Benralizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (all doses)
Study: 36727105
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment for 1 year
Study: 36727222
Drug: Anlotinib in
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib in combination with CAPEOX
Study: 36727222
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with CAPEOX
Study: 36727397
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor therapy
Study: 36727741
Drug: Etoposide plus
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide plus lobaplatin (EL) with concurrent thoracic radiotherapy
Study: 36727741
Drug: Etoposide plus
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide plus cisplatin (EP) with concurrent thoracic radiotherapy
Study: 36727868
Drug: Tulobuterol patch
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol patch (1 mg)
Study: 36728217
Drug: Preemptive antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF)
Study: 36728303
Drug: Low-dose ICG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ICG (0.05 mg)
Study: 36728303
Drug: Standard-dose ICG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ICG (2.5 mg)
Study: 36728653
Drug: Varenicline solution
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline solution nasal spray (VNS) 0.03 mg
Study: 36728874
Drug: Biweekly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly intravitreal aflibercept injections (IAI) 2 mg
Study: 36728974
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily physical activity (PA)
Study: 36729084
Drug: As-needed (PRN)
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As-needed (PRN) ranibizumab therapy
Study: 36729422
Drug: SB2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 therapy for naïve CD patients
Study: 36729422
Drug: SB2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 therapy for switched CD patients
Study: 36729422
Drug: SB2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 therapy for all groups
Study: 36729422
Drug: SB2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 therapy for naïve UC patients
Study: 36729422
Drug: SB2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB2 therapy for switched UC patients
Study: 36729494
Drug: Network-informed personalized
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Network-informed personalized treatment
Study: 36729896
Drug: SIGN@L-A (serious
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIGN@L-A (serious game with playful elements)
Study: 36729896
Drug: SIGN@L-B (serious
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIGN@L-B (serious game with only objectives and feedback)
Study: 36730056
Drug: Tilavonemab 300
Normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilavonemab 300 mg
Study: 36730056
Drug: Tilavonemab 1000
Normalized name: Tilavonemab
DrugBank: Tilavonemab (DB17014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilavonemab 1000 mg
Study: 36730070
Drug: Glutamine administration
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine administration
Study: 36730145
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose TPF (Docetaxel 75 mg/m2, Platinum 75 mg/m2, 5-Fluorouracil 750 mg/m2 IVCI x 5 days) followed by weekly cisplatin (40 mg/m2) or carboplatin (AUC 1.5) concurrent with radiation therapy of 70 Gy over 6.5-7 weeks.
Study: 36730145
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose TPF followed by concurrent chemoradiation.
Study: 36730289
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of AZA or 6-MP
Study: 36730289
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of AZA or 6-MP
Study: 36730749
Drug: Amphetamine Extended-Release
Normalized name: amphetamine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine Extended-Release Oral Suspension
Study: 36731865
Drug: Early angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy initiated within 24 hours of admission.
Study: 36732049
Drug: Efmarodocokin alfa
Normalized name: Efmarodocokin alfa
DrugBank: Efmarodocokin alfa (DB16398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efmarodocokin alfa (30-90 µg/kg doses given once every 2 weeks or monthly for 12 weeks)
Study: 36732571
Drug: Premeal almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premeal almond load (20 g) before OGTT
Study: 36732571
Drug: Premeal almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premeal almond load (20 g) before three major meals
Study: 36732627
Drug: Serplulimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab (3 mg/kg) plus cisplatin (50 mg/m2)
Study: 36732627
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cisplatin (50 mg/m2)
Study: 36732628
Drug: ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab 3 mg/kg plus nivolumab
Study: 36732734
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home spirometry and pulse oximetry in the first three months, followed by once weekly measurements for two years.
Study: 36732830
Drug: Reloading of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reloading of P2Y12 receptor inhibitors
Study: 36733374
Drug: SDI-118, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDI-118, a novel procognitive SV2A modulator
Study: 36733413
Drug: Pre-operative intravenous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intravenous injection of butorphanol
Study: 36733480
Drug: Polyvalent mechanical
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvalent mechanical bacterial lysate (PMBL) therapy
Study: 39739195
Drug: Fezolinetant 30
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 30 mg
Study: 39739195
Drug: Fezolinetant 45
Normalized name: fezolinetant 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 45 mg
Study: 36734235
Drug: DAPT using
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT using cilostazol and either aspirin or clopidogrel (464 patients)
Study: 36734235
Drug: SAPT using
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAPT using aspirin or clopidogrel alone (461 patients)
Study: 36734235
Drug: SAPT using
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAPT using aspirin or clopidogrel
Study: 36734294
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) combined with low-dose apatinib (500 mg daily)
Study: 36734354
Drug: GLP-1 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (1.5 pmol/kg per minute) with 0.9% NaCl infusion (750 mL/h)
Study: 36734354
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 0.9% NaCl infusion (750 mL/h)
Study: 36734415
Drug: Allogeneic umbilical
Normalized name: Allogeneic umbilical cord mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic umbilical cord blood (UCB) therapy, infused once intravenously
Study: 36734848
Drug: Ferumoxytol-enhanced MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol-enhanced MRI before treatment with liposomal irinotecan (nal-IRI)
Study: 36735117
Drug: Letrozole, everolimus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole, everolimus, and carotuximab (letrozole 2.5 mg PO daily, everolimus 10 mg PO daily, carotuximab 15 mg/kg IV every 2 weeks)
Study: 36735635
Drug: Preoperative preparation-themed
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation-themed storybook (Elif Has Surgery) read by mother for 10 minutes
Study: 36735745
Drug: GSK3772847 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3772847 (10 mg/kg) administered intravenously at Weeks 0, 4, and 8
Study: 36735745
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously at Weeks 0, 4, and 8
Study: 36735745
Drug: GSK3772847 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3772847 (10 mg/kg)
Study: 36735896
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg once every 3 weeks and apatinib 250 mg once per day
Study: 36735931
Drug: Balanced Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Solution
Study: 36735937
Drug: Pulsed Field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Field Ablation (PFA) system with variable-loop circular catheter, at least 12 applications per vein; adenosine/isoproterenol administered to confirm entrance block.
Study: 36736112
Drug: Jitongning Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitongning Tablet (JTNT)
Study: 36736209
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 0.6 μg/kg over 10 min, followed by continuous infusion of 0.5 μg/kg/h until 1 h before end of surgery)
Study: 36736339
Drug: Increased adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increased adalimumab dose intervals to 40 mg every 3 weeks, further to every 4 weeks if in remission at week 24.
Study: 36736339
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of adalimumab at 40 mg every 2 weeks.
Study: 36736339
Drug: Increased adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increased adalimumab dose intervals (intervention group).
Study: 36736339
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of adalimumab (control group).
Study: 36737276
Drug: Maintenance oral
Normalized name: Cystex Urinary Health Maintenance oral soluti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance oral etoposide
Study: 36737276
Drug: Maintenance oral
Normalized name: Cystex Urinary Health Maintenance oral soluti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance oral etoposide in platinum-refractory patients
Study: 36737440
Drug: Azacytidine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacytidine treatment in MDS patients
Study: 36737825
Drug: Ezetimibe tablet
Normalized name: Ezetimibe Tablets
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe tablet (10 mg)
Study: 36737825
Drug: Ezetrol® (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetrol® (10 mg)
Study: 36738100
Drug: ASP8062 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8062 60 mg
Study: 36738333
Drug: TAK-164 (0.064
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-164 (0.064 mg/kg)
Study: 36738333
Drug: TAK-164 (0.032-0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-164 (0.032-0.25 mg/kg)
Study: 36738756
Drug: Whole-breast irradiation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-breast irradiation (25 daily fractions of 50 Gy over 5 weeks with a supplemental boost of 10 Gy)
Study: 36738756
Drug: APBI using
Approvals — FDA: no, EMA: no, PMDA: no
Description: APBI using multicatheter brachytherapy (30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions over 5 days, or 50 Gy of pulsed-dose-rate brachytherapy over 5 days)
Study: 36738762
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (subcutaneous golimumab 200 mg at week 0, subcutaneous golimumab 100 mg at weeks 2, 6, and 10, intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks for 32 weeks)
Study: 36738762
Drug: Golimumab monotherapy
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab monotherapy (subcutaneous golimumab 200 mg at week 0 followed by subcutaneous golimumab 100 mg at week 2 and every 4 weeks thereafter for 34 weeks)
Study: 36738762
Drug: Guselkumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab monotherapy (intravenous guselkumab 200 mg at weeks 0, 4, and 8, followed by subcutaneous guselkumab 100 mg every 8 weeks thereafter for 32 weeks)
Study: 36738762
Drug: Guselkumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab monotherapy
Study: 36738929
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation (74 Gy)
Study: 36739136
Drug: Genotype-guided drug
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided drug treatment (n=3342)
Study: 36739136
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients receiving genotype-guided treatment (n=2923)
Study: 36739258
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) and oral acetazolamide (OA) combination therapy (250mg twice daily)
Study: 36739258
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) monotherapy
Study: 36739285
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) or Tamoxifen + Aromatase Inhibitors (TAM-AI)
Study: 36739285
Drug: GnRHa (Gonadotropin-Releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa (Gonadotropin-Releasing Hormone Agonists)
Study: 36739457
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of PMVs and MMVs with radiation dose
Study: 36739508
Drug: Weekly attack
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly attack frequency recording
Study: 36739595
Drug: μ-opioid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: μ-opioid receptor agonists (MORAs)
Study: 36739866
Drug: Conventional ESA
Normalized name: esafoxolaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ESA treatment (standardized to weekly intravenous epoetin)
Study: 36740715
Drug: chidamide +
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: chidamide + JAK inhibitor ruxolitinib
Study: 36740814
Drug: Olorinab 50
Normalized name: Olorinab
DrugBank: Olorinab (DB14998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olorinab 50 mg
Study: 36741122
Drug: Routine assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine assessment and effective treatment of anhedonia
Study: 36741404
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with a live attenuated vaccine
Study: 36742008
Drug: Curcumin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin and quercetin (CUR-QUE) oral supplement
Study: 36744469
Drug: Active hypertension
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active hypertension treatment
Study: 36744737
Drug: Autologous whole
Normalized name: Autologous whole blood product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous whole blood clot treatment
Study: 36745273
Drug: Early recognition,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early recognition, monitoring, and treatment of APOs
Study: 36745299
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with UC with CRP > 5 mg/dl
Study: 36745299
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with UC with Fcal > 250 mg/kg
Study: 36745299
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with IBD with CRP < 5 mg/dl
Study: 36745299
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with IBD with Fcal < 250 mg/kg
Study: 36745371
Drug: Roflumilast cream
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast cream 0.05%
Study: 36745371
Drug: Roflumilast cream
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast cream 0.15% and 0.05%
Study: 36745371
Drug: Roflumilast cream
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast cream
Study: 36745412
Drug: Quarterly antibiotic
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly antibiotic prescribing audit and feedback with peer benchmarking
Study: 36745422
Drug: Shed-MEDS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shed-MEDS intervention (pharmacist- or nurse practitioner-led comprehensive medication review, deprescribing recommendations, and actions initiated in the hospital and continued in PAC)
Study: 36745684
Drug: Fortified BEP
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified BEP supplements and iron-folic acid (IFA) tablets during pregnancy
Study: 36746169
Drug: Immediate PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg daily)